Home » Topics » Regulatory

Regulatory
RSS

Once-daily antidiabetic drug from Andrx steadily advances towards market launch

Jan. 11, 2000

New combination therapy for depression with reduced side effects

Jan. 11, 2000

Pharmacia & Upjohn seeks approval for combination glaucoma therapy

Jan. 11, 2000

FDA approves liquid formulation of Celexa for treatment of depression

Jan. 10, 2000

The antiplatelet agent triflusal now shown to inhibit NF-kappaB activation

Jan. 10, 2000

Olanzapine and fluoxetine in combination useful for refractory depression

Jan. 10, 2000

Miltefosine tested as oral treatment for leishmaniasis

Jan. 4, 2000

CFC-free flunisolide to be developed by 3M/Forest partnership

Jan. 3, 2000

NDA filed for intranasal scopolamine during fourth quarter

Jan. 3, 2000

FDA approves Ligand's Targretin Capsules for treatment of CTCL

Dec. 30, 1999

Popular Stories

Today's news in brief
BioWorld
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
New mechanism of action identified for QC-6352
BioWorld Science
QC-6352 is a small molecule developed to inhibit the histone demethylase 4 (KDM4) that has shown potent antitumoral activity and which has a derivative named...
First-in-class pan-inflammasome blocker for hidradenitis suppurativa
BioWorld Science
Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.
SCAN is core circuit affected in Parkinson’s disease
BioWorld
Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...